Cynata Therapeutics (OTCMKTS:CYYNF) Shares Down 27.9% – Time to Sell?

Cynata Therapeutics Limited (OTCMKTS:CYYNFGet Free Report)’s stock price fell 27.9% during mid-day trading on Friday . The stock traded as low as $0.14 and last traded at $0.14. 1,111 shares traded hands during mid-day trading, an increase of 789% from the average session volume of 125 shares. The stock had previously closed at $0.19.

Cynata Therapeutics Stock Performance

The business’s 50 day moving average price is $0.14 and its 200-day moving average price is $0.17.

About Cynata Therapeutics

(Get Free Report)

Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease.

Recommended Stories

Receive News & Ratings for Cynata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cynata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.